MDLN at a glance
Medline Inc (MDLN, SEC CIK 2046386) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01.
- As of September 30, 2026, 36 institutional investment managers tracked by SignalX reported holding Medline Inc (MDLN) shares worth $16.1 billion in 13F-HR filings.
- In the last 90 days, MDLN insiders reported 0 open-market purchases ($0) and 6 open-market sales ($996.4M) on Form 4, a net sale of $996.4M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $28.4B
- +11.5% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$996.4M
- 13F holders
- 36 funds
- $16.1B · +0 vs prior quarter
- Latest 8-K
- Nov 18, 2026
- Item 1.01 · Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 26, 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 Form 10-K
- Carried-forward risks remain unchanged for the quarter
Management Discussion & Analysis
- Quarterly revenue $7,856M, up 10.4% YoY from $7,115M, driven by organic volume growth
- Gross margin 24.5% vs 26.4% YoY; net income margin 4.0% vs 4.5%; Adjusted EBITDA margin 12.2% vs 12.1%
- Best segment: Medline Brand revenue $3,637M, up 6.6%, EBITDA margin 25.9% vs 24.1%; worst: Supply Chain Solutions margin 4.4% vs 5.5%
- Cash and equivalents $2,321M, short-term investments $1,287M; nine-month operating cash flow $2,152M vs $1,515M
- Headwinds: tariffs, FDA bed recall costs $60M to $210M, restructuring costs $20M to $30M; 2026 capital expenditures up to $600M
AI summary of the MDLN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- $200 million private repurchase of Class A shares and Medline Holdings Common Units from major institutional stockholders
- Repurchase price equal to the Offering underwriting price, aligning transaction economics with the concurrent offering
Item 8.01: Other Events
- Secondary offering of 60,000,000 Class A shares by selling stockholders
- Approximately $2.1 billion net proceeds to selling stockholders, not Medline
Item EX-99.1: Item EX-99.1
- Secondary offering priced at $35.50 per share for 60 million shares, with a 9 million-share underwriter option
- Selling stockholders receive proceeds, not Medline, limiting dilution and providing no new corporate capital
Item 2.02: Results of Operations and Financial Condition
- Medline’s Q3 and first-nine-month results released for period ended September 26, 2026
- Investors should review Exhibit 99.1 for revenue, earnings, margins and outlook details
Item EX-99.1: Item EX-99.1
- Q3 net sales $7.9B, up 10.4%, while net income fell 1.2% to $318M, signaling growth with margin pressure
- Q3 Adjusted EBITDA $960M, up 11.8%, but gross margin declined to 24.5% from 26.4%
Item 7.01: Regulation FD Disclosure
- Voluntary exit from all Medline Brand beds and related products, eliminating a Front Line Care product line
- Affected products generated approximately $60 million in sales over the twelve months ended June 27, 2026
AI summaries of MDLN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MDLN
Don't miss the next MDLN filing
- Alerts as it files. A push when MDLN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MDLN, by share count.
- Ask anything. An AI agent that reads every MDLN filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| CP Circle ML Holdco GP, LLC | J | Nov 18, 2026 | 483,874 | - |
| CP Circle ML Holdco GP, LLC | C | Nov 18, 2026 | 483,874 | - |
| BX Mozart ML-1 Holdco L.P. | C | Nov 18, 2026 | 129,634 | - |
| CP Circle ML Holdco GP, LLC | C | Nov 18, 2026 | 483,874 | - |
| BX Mozart ML-1 Holdco L.P. | J | Nov 18, 2026 | 857,785 | - |
| BX Mozart ML-1 Holdco L.P. | J | Nov 18, 2026 | 129,634 | - |
| BX Mozart ML-1 Holdco L.P. | C | Nov 18, 2026 | 129,634 | - |
| BX Mozart ML-1 Holdco L.P. | C | Nov 18, 2026 | 857,785 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $23.2B | $25.5B | $28.4B |
| Gross Profit | - | $7.0B | $7.5B |
| Operating Income | $1.3B | $2.1B | $2.2B |
| Net Income | - | $1.2B | $1.2B |
| Gross Margin | - | 27.3% | 26.4% |
| Op. Margin | 5.4% | 8.4% | 7.8% |
| Net Margin | - | 4.6% | 4.1% |
| Balance Sheet | |||
| Total Assets | - | $36.0B | $38.5B |
| Equity | - | - | $10.7B |
| ROE | - | - | 10.8% |
| Per Share | |||
| EPS | - | - | $-0.01 |
| Cash Flow | |||
| Operating CF | $1.7B | $1.8B | $1.7B |
| CapEx | $275.0M | $354.0M | $447.0M |
Source: XBRL data in Medline Inc (MDLN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MDLN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 36 | $16.13B |
| Q2 2026 | 36 | $19.39B |
| Q1 2026 | 33 | $20.79B |
| Q4 2025 | 26 | $19.40B |
- Vanguard Portfolio Management LLC+7.06M (+42%)
- Vanguard Capital Management LLC+6.93M (+39%)
- Principal Financial Group+4.46M (+345%)
- JPMorgan Chase & Co+4.44M (+718%)
- Invesco Ltd+2.09M (+5%)
- Goldman Sachs Group−2.90M (-61%)
- T. Rowe Price Group−1.38M (-28%)
- Millennium Management−858.4K (-81%)
- Soros Fund Management−634.9K (-39%)
- Morgan Stanley−238.2K (-1%)
- FMR LLC (Fidelity)−46.96M
- Viking Global Investors−4.84M
- Ameriprise Financial−22.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 131 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MDLN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 8-K | Nov 18, 2026 | - | Analysis | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 10-Q | Nov 4, 2026 | Sep 26, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Oct 21, 2026 | - | Analysis | - |
| 8-K | Oct 15, 2026 | - | Analysis | - |
| 4 | Oct 13, 2026 | - | - | - |
| 4 | Oct 6, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 4 | Aug 17, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
MDLN SEC filings: frequently asked questions
Are MDLN insiders buying or selling?
In the last 90 days, Medline Inc (MDLN) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $996.4 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MDLN stock?
As of September 30, 2026, the largest Medline Inc (MDLN) holders among the 13F filers tracked by SignalX were Carlyle Group ($6.5 billion), Blackstone Group ($3.5 billion), Invesco Ltd ($1.4 billion), BlackRock ($921.3 million), Vanguard Capital Management LLC ($858.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MDLN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Medline Inc (MDLN) reported revenue of $28.4 billion (up 11.5% from FY2024) and net income of $1.2 billion. Diluted EPS was -$0.01. The figures come from the XBRL data in the 10-K.
What did MDLN report in its latest 8-K?
Medline Inc (MDLN) filed an 8-K on November 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement) and Item 8.01 (Other Events). $200 million private repurchase of Class A shares and Medline Holdings Common Units from major institutional stockholders.
What are the latest MDLN SEC filings?
Medline Inc (MDLN) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on November 19, 2026.
What is MDLN's SEC CIK number?
Medline Inc (MDLN)'s SEC Central Index Key (CIK) is 2046386. EDGAR lists every MDLN filing under that number.
Ask anything about MDLN
The research agent reads MDLN's filings, financials, insider trades and 13F holders, then answers with sources.